慢性鼻-鼻窦炎中的生物制剂：现状与展望
Biologics in Chronic Rhinosinusitis: Current and Emerging.
机构信息
Department of Otolaryngology - Head and Neck Surgery, University of Colorado Anschutz School of Medicine, 12631 East 17th Avenue, MSB 205 Room 3001, Aurora, CO 80045, USA.
Department of Otolaryngology - Head and Neck Surgery, University of Colorado Anschutz School of Medicine, 12631 East 17th Avenue, MSB 205 Room 3001, Aurora, CO 80045, USA.
出版信息
Immunol Allergy Clin North Am. 2024 Nov;44(4):657-671. doi: 10.1016/j.iac.2024.07.005. Epub 2024 Aug 17.
Chronic rhinosinusitis (CRS) is categorized phenotypically into CRS with and without nasal polyps (CRSwNP, CRSsNP). Endotyping categorizes the disease based on immune cell activity and inflammatory mechanisms into Type 1, Type 2, and Type 3. The Type 2 endotype is the most researched and associated with asthma, atopic disease, and severe CRSwNP. For patients with poorly controlled CRSwNP, there are 3 approved biologic treatments: omalizumab, dupilumab, and mepolizumab. Many other biologics are being tested in Type 2, non-Type 2, and mixed endotypes in CRSwNP and CRSsNP. These studies will play a significant role in shaping the future of CRS management.
慢性鼻-鼻窦炎（CRS）根据是否伴有鼻息肉分为伴有鼻息肉的慢性鼻-鼻窦炎（CRSwNP）和不伴有鼻息肉的慢性鼻-鼻窦炎（CRSsNP）两种表型。基于免疫细胞活性和炎症机制对疾病进行的分类称为“分型”，可分为 1 型、2 型和 3 型。2 型表型是研究最多的表型，与哮喘、特应性疾病和重度 CRSwNP 相关。对于未得到良好控制的 CRSwNP 患者，目前有 3 种已批准的生物制剂治疗药物：奥马珠单抗、度普利尤单抗和美泊利珠单抗。许多其他生物制剂也正在 CRSwNP 和 CRSsNP 的 2 型、非 2 型和混合表型中进行测试。这些研究将在塑造 CRS 管理的未来方面发挥重要作用。
Zotero 插件